Clinical trial NCT01577706: Spectroscopic Imaging at 4T: A Drug Challenge Study
Official title: Spectroscopic Imaging of GABA and Glutamate/Glutamine in Healthy Volunteers at 4T: A Double Blind, Crossover Drug Challenge Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: AOD Effects and Consequences
Keywords: GABA
glutamate
glutamine
spectroscopy
brain
imaging
alprazolam
dextroamphetamine
placebo
Lead sponsor: Mclean Hospital
Sponsor class: OTHER
First posted: 2012-04-16
Enrollment: 7
Sex: MALE
Minimum age (years): 21
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: An advanced technique for rapid magnetic resonance proton spectroscopic imaging (1H-MRSI) will be employed in a drug challenge study in healthy volunteers to spatially map and measure acute changes in the brain chemicals GABA, glutamate and glutamine after administration of a drug. Three condition will be tested in a double-blind fashion, i)depressant, ii)stimulant, iii)placebo. It is hypothesized that unique and reproducible spatial and directional metabolic response patterns will be observed, unique to each condition within the brain.

Detailed description: Proton magnetic resonance spectroscopy (1H MRS) is a powerful tool for assessing neurochemistry non-invasively in vivo. However, the primary shortcoming in most studies is the lack of spatial coverage afforded by the typical single-voxel design. Limits on participant tolerance and financial resources restrict single-voxel studies to an examination of one or two carefully chosen voxels per scan, thus inadequately addressing the question of focal vs. global pathophysiology. A secondary shortcoming is that most studies report on either GABA or glutamate-glutamine (Glu-Gln) due to the technically demanding spectral-editing techniques that must be implemented in order to resolve and quantify those metabolites with any accuracy.

1H MRS imaging (MRSI) can partially overcome these limitations by providing a global picture of brain chemistry rather than just the focal snapshot afforded by the single-voxel design. However, the scan time necessary for collecting enough data for adequate spatial resolution and signal-to-noise, particularly if also using specialized spectral-editing techniques, is still too lengthy. We recently developed a method that combines Spectroscopic Imaging with the MEGAPRESS-based difference-editing acquisition for optimal GABA detection as well as for optimal detection of Glu and Gln. This MEGACSI sequence will permit us to obtain the maximum amount of neurochemical information in a clinically sound scan time, while using the current state-of-the-art MRS editing methods for optimal detection of GABA, Glu, and Gln.

Eligibility criteria: Inclusion Criteria:

* Participants will be male volunteers between the ages of 21-45
* Non-smoking participants are preferred, but will admit those who smoke less than 5 cigarettes per day
* Participants must be able to read screening materials including consent form and give informed consent

Exclusion Criteria:

* Participants cannot meet DSM-IV criteria for lifetime and/or current mood, anxiety, psychotic, and alcohol/drug use disorders as identified by the SCID
* Participants cannot be taking any prescription medication (except oral contraceptives, certain short-term anti-fungal agents, and some topical creams for dermal conditions) or nutritional supplements
* Participants cannot be taking any psychotropic medications
* Participants cannot have a history of major head trauma resulting in cognitive impairment, seizure, or other neurological disorders.
* Participants cannot have any conditions that are contraindicated for MRI
* Participants cannot have a family history of alcoholism
* Participants cannot have any abnormal blood chemistries/urinalysis results or any other medical condition that may affect drug disposition (e.g., Hepatitis C)
* Participants cannot have current or past cardiac problems, and they also cannot have a family history of sudden death or ventricular arrhythmia
* Participants who, in the investigators' judgment, will not likely be able to comply with the study protocol.
* Participants cannot have any clinically significant findings in the structural anatomic brain scans (per the MRI report read by a board-certified radiologist).

Primary outcomes:
measure: Left Thalamus: Percent Change in GABA Levels After an Acute Drug Challenge
timeFrame: from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)
measure: Left Basal-Ganglia: Percent Change in GABA Levels After an Acute Drug Challenge
timeFrame: from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)
measure: Left Temporal: Percent Change in GABA Levels After an Acute Drug Challenge
timeFrame: from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)
measure: Parieto-Occipital: Percent Change in GABA Levels After an Acute Drug Challenge
timeFrame: from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)
measure: Right Thalamus: Percent Change in GABA Levels After an Acute Drug Challenge
timeFrame: from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)
measure: Right Basal-Ganglia: Percent Change in GABA Levels After an Acute Drug Challenge
timeFrame: from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)
measure: Right Temporal: Percent Change in GABA Levels After an Acute Drug Challenge
timeFrame: from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)
Secondary outcomes:
Other outcomes:
Locations:
city: Belmont
country: United States
facility: McLean Imaging Center, McLean Hospital
state: Massachusetts
Study officials:
affiliation: Mclean Hospital
name: John E Jensen, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: